Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome (PCOS)

Abstract

Metformin and changes in serum lipid profile in lean patients with polycystic ovary syndrome Wpływ metforminy na profil lipidowy pacjentek z zespołem policystycznych jajników i prawidłową należną masą ciała M. Kiałka et al. Introduction: The aim of our study was to assess the values of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides before and after treatment with metformin in lean patients with polycystic ovary syndrome (PCOS). Material and methods: 32 patients received metformin 1500 mg per day in three divided doses. Lipids measurements were performed twice: before and after 6 months of treatment with metformin. Results: In lean patients with PCOS after treatment with metformin we observed: statistically significant lower LDL-C levels (4.16±0.79 mmol/l vs 3.4±0.86 mmol/l, p<0.05) and triglycerides levels (1.8±0.53 mmol/l vs 1.12±0.64 mmol/l, p<0.05). We observed an increase in HDL values and a decrease in total cholesterol values, but these changes were not statistically significant (1.5±0.71 mmol/l vs 1.71±0.69 mmol/l, p=0.09; 5.87±0.92 mmol/l vs 5.69±0.97 mmol/l, p=0.11). Conclusion: Our study showed that treatment of 1500 mg metformin for about six months among PCOS women results in an improvement in serum lipid profiles. We observed a significant decrease in LDL-C and triglycerides values after metformin therapy. Wnioski: Wykazano, że leczenie metforminą w dawce 1500 mg przez okres sześciu miesięcy skutkuje poprawą profilu lipidowego u pacjentek z PCOS i prawidłową należną masą ciała. Zaobserwowano istotny spadek wartości cholesterolu LDL i triglicerydów po leczeniu metforminą.

Effectiveness of Probiotics, Metformin and Their Combination Therapy in Ameliorating Dyslipidemia Associated With PCOS

“…Another study by Kailka et al mentioned the beneficial effects of Metformin on lean women with polycystic ovarian syndrome with displayed significant decrease in the TG and LDL-C levels [35].…”

“…Metformin is one of most comprehensively researched drug, which shows remarkable efficacy in lessening insulin resistance in patients with or without PCOS, but shows variable results in improving dyslipidemia associated with this syndrome, despite the fact that insulin resistance in some way is linked with the same [14,15].…”

Modern Ways of Treatment of Metabolic Disorders in Women with Polycystic Ovarian Syndrome

“…According to scientific research the effect of metformin on content of atherogenic lipids is variable [15,16].…”